WO2016140630A1 - An effervescent composition comprising levocetirizine and pseudoephedrine - Google Patents
An effervescent composition comprising levocetirizine and pseudoephedrine Download PDFInfo
- Publication number
- WO2016140630A1 WO2016140630A1 PCT/TR2015/000089 TR2015000089W WO2016140630A1 WO 2016140630 A1 WO2016140630 A1 WO 2016140630A1 TR 2015000089 W TR2015000089 W TR 2015000089W WO 2016140630 A1 WO2016140630 A1 WO 2016140630A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition according
- acid
- effervescent composition
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Definitions
- the present invention relates to the preparation of stable pharmaceutical compositions comprising levocetirizine and pseudoephedrine.
- Levocetirizine which is an R-enantiomer of cetirizine is a piperazine derivative, potent and selective H1 receptor antagonist.
- Levocetirizine, chemical name is (2- ⁇ 4 ⁇ [(R)-(4-Chlorophenyl) (phenyl)methyl]-1-piperazinyl ⁇ ethoxy)acetic acid.
- Levocetirizine is an antihistaminic agent. It works by blocking a substance in the body called histamine. This helps to decrease allergy symptoms and hives. Levocetirizine is used to relieve runny nose; sneezing; and redness, itching, and tearing of the eyes caused by hay iever, urticaria, seasonal allergies, and allergies to other substances such as dust mites, animal dander, and mold. It is also used to treat symptoms of hives, including itching and rash.
- Pseudoephedrine is a member of decongestant drugs. Pseudoephedrine and its pharmaceutically acceptable salts are well recognized by those skilled in the art as safe and effective nasa! and ocular decongestants.
- Pseudoephedrine chemical name is (1S,2S)-2-( ethylamino)-1-phenyl-1-propanol.
- Pseudoephedrine is a well known for shrinking swollen nasal mucous membranes. It reduces tissue hyperemia, edema, and nasal congestion commonly associated with colds or allergies. Other beneficial effects may include increasing the drainage of sinus secretions, and opening of obstructed Eustachian tubes. It is also indicated for vasomotor rhinitis, and as an adjunct to other agents in the optimum treatment of allergic rhinitis, croup, sinusitis, otitis media, and tracheobronchitis.
- Pseudoephedrine can be used either as oral or topical decongestant.
- the advantage of oral pseudoephedrine over topical nasal preparations is that it does not cause rebound congestion (rhinitis medicamentosa).
- WO2011/146032 discloses effervescent composition of levocetirizine.
- EP0811374 disclose a pharmaceutical composition comprising cetirizine and pseudoephedrine; US Patent 6,171 ,618 discloses a dosage form containing cetirizine as an immediate release component and pseudoephedrine as a controlled release component, a portion of the pseudoephedrine can be incorporated as an immediate release component.
- EP 1404304 A1 A tablet comprising at least two distinct segments one segment of which comprises as active ingredient predominantly cetirizine and a second segment of which comprises as active ingredient predominantly pseudoephedrine.
- WO2010/078541 describes a pharmaceutical composition comprising drug layer comprising drug particles comprising naproxen and cetirizine and another drug layer comprising pseudoephedrine, for treating symptoms of upper respiratory allergies, nasal congestion, and headache.
- An effervescent pharmaceutical composition characterized in that it comprises:
- present invention relates to an effervescent composition
- an effervescent composition comprising:
- levocetirizine means levocetirizine or pharmaceutically acceptable salt thereof.
- pseudoephedrine means pseudoephedrine or pharmaceutically acceptable salt thereof.
- Effervescent formulation of the present invention can be in powder, granule or tablet form. Effervescent formulation of the present invention is preferably in tablet form.
- the composition of the present invention is in the form of an effervescent tablet intended to be dissolved or dispersed in water before administration and generally contains acid substances and carbonates or bicarbonates, which react rapidly in the presence of water releasing carbon dioxide.
- the effervescent tablets comprise effervescent couples selected from, but not limited to, thermolabile gas generating agents such as sodium bicarbonate, sodium glycine carbonate, potassium bicarbonate, ammonium bicarbonate, sodium bisulfite, sodium metabisulfite, and an acid source such as citric acid, maleic acid or tartaric acid.
- acid and base components are in the separate compartments.
- compositions of this invention may be used in the treatment of vasomotor rhinitis. It can be reduced rhinitis and asthma symptoms and improved overall quality of life. It is indicated for the relief of nasal and non-nasal symptoms associated with seasonal or perennial allergic rhinitis in adults and children 12 years of age and older.
- This invention can be used for the treatment of allergies, hay fever, pollen, dust, mold and tree allergies.
- this invention is used to relieve allergy symptoms such as watery eyes, runny/stuffy nose, itching eyes/nose, and sneezing.
- This invention may be used for the treatment of nasal congestion, sinus congestion, Eustachian tube congestion, and vasomotor rhinitis, and as an adjunct to other agents in the optimum treatment of allergic rhinitis, croup, sinusitis, otitis media, and tracheobronchitis.
- This invention can include production method which is for increasing solubility. This method can be used in wet granulation.
- An important subject of the present invention is to provide a formulation which has resistant against physical and enviromental conditions and also have a high bioavailability.
- the present invention provides pharmaceutical formulations comprising active ingredients combination characterized by 1) good stability properties, 2 ⁇ controfiing the release of the active ingredient according to desired therapeutical needs, and finally 3) simple and also competitive manufacturing process.
- levocetirizine may be effectively combined with pseudoephedrine, comparing with single activity of each of these and with an enhancement of the activity of pseudoephedrine and other compounds.
- composition of the present invention may comprise one or more pharmaceutically acceptable excipient(s).
- Pharmaceutically acceptable excipients comprise, but are not limited to, fillers, disintegrants, solvents, acid substance, base substance, binders, lubricants, glidants, sweeteners, aromatic agents, flavouring agents, preservatives, coloring agents, and the mixtures thereof.
- Binders can be selected from the group, but are not limited to, methylcellulose, sodium carboxymethycellulose, calcium carboxymethycellulose, ethylcellulose, hydroxypropyl methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, silicified microcrystalline cellulose(SMCC), polyvinylpyrrolidone, gelatine, polyvinyl alcohol, acacia, tragacanth, guar, pectin, starch paste, potato starch, corn starch, wheat starch, pre-gelatinized starch, alginic acid, compressible sugar, liquid glucose, dextrates, dextrin, dextrose, ma!todextrin, guar gum, magnesium aluminium silicate, polymethacrylates, sorbitol, natural-synthetic gums and other materials known to one of ordinary skill in the art.
- a mixture of binders may also be used.
- Diluents may be water-soluble or water insoluble. Diluents can be selected from the group, but are not limited to, spray-dried or anhydrous lactose, sucrose, dextrose, starch, pre-geiatinized starch, mannitol, maltitol, sorbitol, xylitol, dextrin, cellulose derivatives including powdered cellulose, microcrystalline cellulose, dibasic calcium phosphate, tribasic calcium phosphate and calcium sulphate, kaolin, precipitated calcium carbonate, maltodextrin and other materials known to one of ordinary skill in the art. A mixture of diluents may also be used.
- Lubricants can be selected from the group, but are not limited to, vegetable oils, such as hydrogenated vegetable oil or hydrogenated castor oil; polyethylene glycols, such as polyethylene glycol (PEG)-4000 and PEG-6000; stearic acid; derivatives of stearic acid, such as magnesium stearate, sodium stearate, calcium stearate, zinc stearate, glyceryl monostearate, glyceryl palmitostearate and sodium stearyl fumarate; mineral salts, such as talc; inorganic salts; organic salts, such as sodium benzoate, sodium acetate, sodium chloride and sodium oleate; and polyvinyl alcohols, microcrystalline cellulose, sodium lauryl sulphate, silica, colloidal silica, cornstarch, calcium silicate, magnesium silicate, silicon hydrogel and other materials known to one of ordinary skill in the art.A mixture of lubricants may also be used.
- vegetable oils such as hydrogenated vegetable oil or hydrogenated
- Gtidants can be selected from the group, but are not limited to, colloidal silicon dioxide, colloidal silica, cornstarch, talc, calcium silicate, magnesium silicate, magnesium trisiiicate, amorphous silica, colloidal silicon, silicon hydrogel, powdered cellulose, silicon dioxide, talc, tribasic calcium phosphate and other materials known to one of ordinary skill in the art. A mixture of glidants may also be used.
- Flavoring agents including, but not limited to, black current, sodium chloride, strawberry, peppermint, menthol, artificial vanilla, cinnamon, various fruit flavors, natural aroma oils (such as peppermint oil, oil of wintergreen, clove bud oil, parsley oil, eucalyptus oil, lemon oil, orange oil), menthane, anethole, methyl salicylate, eucalyptol, methyl acetate, sage, 1-eugenol, oxanon, alpha-irisone, marjoram, lemon, orange, blackberry, propenyl guaetol acetyl, vanilla, timole, linalol, cinnamaldehyde glycerol acetal, N-substituted p-menthane-3-carboxamide and other materials known to one of ordinary skill in the art.
- a mixture of flavoring agents may also be used.
- Sweeteners including, but not limited to, sugars such as sucrose, glucose (corn syrup), invert sugar, fructose, and mixtures thereof; saccharin and its various salts such as sodium or calcium salt; cyclamic acid and its various salts such as sodium salt; the dipeptide sweeteners such as aspartame; dihydrochalcone; glycyrrhizin; Stevia rebaudiana (Stevioside); and sugar alcohols such as sorbitol, sorbitol syrup, D- tryptophan, monoammonium glycyrrhizinate, neohesperidin, dihydrochalcone, thaumatin, neotam, alitam, cyclamates,mannitol, xylitol, and the like.
- a combination of sweeteners and flavoring agents can also be used.
- Buffering agents can be selected from the group, but not limited to, potassium bicarbonate, citric acid, glycine, arginine, sodium acetate and sodium citrateand other materials known to one of ordinary skill in the art, and the mixtures thereof.
- Acid substance can be selected from the group, but not limited to, ascorbic acid, citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, lactic acid, oxalic acid, formic acid, benzene sulfonic add, benzoic acid, maleic acid, glutamic acid, succinic acid, aspartic acid, diatrizoic acid, acetic acid and acid anhydrides and acid salts thereof, and mixtures thereof.
- the acidifying agent may also be an inorganic acid, such as hydrochloric acid, sulfuric acid, phosphoric acid, and nitric acid.
- Base substance can be selected from the group, but not limited to, aluminum salts such as magnesium aluminum silicate; magnesium salts such as magnesium carbonate, magnesium trisiiicate, magnesium stearate; calcium salts such as calcium carbonate; bicarbonates such as calcium bicarbonate and sodium bicarbonate; phosphates such as monobasic calcium phosphate, dibasic calcium phosphate, dibasic sodium phosphate, tribasic sodium phosphate (TSP), dibasic potassium phosphate, tribasic potassium phosphate; metal hydroxides such as aluminum hydroxide, sodium hydroxide and magnesium hydroxide; metal oxides such as magnesium oxide; N-methyl glucami ' ne; arginine and salts thereof; amines such as monoethanolamine, diethanolamine, triethanolamine, and tris(hydroxymethyl)aminomethane (TRIS) and other materials known to one of ordinary skill in the art, and the mixtures thereof.
- the pharmaceutical formulation are produced by one of the dry granulation, dry blending, direct compression,
- the method proposed for production of the formulations of the present invention is preferably wet granulation method and it basically comprises the following steps;
- the granulation solution to be used in the production of the formulations of the present invention comprise a pharmaceutically acceptable solvent in an effective amount and at least one binder.
Abstract
The present invention relates to the preparation of effervescent compositions comprising a levocetirizine and pseudoephedrine.
Description
AN EFFERVESCENT COMPOSITION COMPRISING LEVOCETIRIZINE AND
PSEUDOEPHEDRINE
Field of invention
The present invention relates to the preparation of stable pharmaceutical compositions comprising levocetirizine and pseudoephedrine.
Background of the invention
Levocetirizine which is an R-enantiomer of cetirizine is a piperazine derivative, potent and selective H1 receptor antagonist. Levocetirizine, chemical name is (2-{4~[(R)-(4-Chlorophenyl) (phenyl)methyl]-1-piperazinyl}ethoxy)acetic acid.
Formula 1 : Levocetirizine
Levocetirizine is an antihistaminic agent. It works by blocking a substance in the body called histamine. This helps to decrease allergy symptoms and hives. Levocetirizine is used to relieve runny nose; sneezing; and redness, itching, and tearing of the eyes caused by hay iever, urticaria, seasonal allergies, and allergies to other substances such as dust mites, animal dander, and mold. It is also used to treat symptoms of hives, including itching and rash.
Pseudoephedrine is a member of decongestant drugs. Pseudoephedrine and its pharmaceutically acceptable salts are well recognized by those skilled in the art as safe and effective nasa! and ocular decongestants.
Pseudoephedrine, chemical name is (1S,2S)-2-( ethylamino)-1-phenyl-1-propanol.
Formula 2: Pseudoephedrine
Pseudoephedrine is a well known for shrinking swollen nasal mucous membranes. It reduces tissue hyperemia, edema, and nasal congestion commonly associated with colds or allergies.
Other beneficial effects may include increasing the drainage of sinus secretions, and opening of obstructed Eustachian tubes. It is also indicated for vasomotor rhinitis, and as an adjunct to other agents in the optimum treatment of allergic rhinitis, croup, sinusitis, otitis media, and tracheobronchitis.
Pseudoephedrine can be used either as oral or topical decongestant. The advantage of oral pseudoephedrine over topical nasal preparations is that it does not cause rebound congestion (rhinitis medicamentosa).
WO2011/146032 discloses effervescent composition of levocetirizine.
EP0811374 disclose a pharmaceutical composition comprising cetirizine and pseudoephedrine; US Patent 6,171 ,618 discloses a dosage form containing cetirizine as an immediate release component and pseudoephedrine as a controlled release component, a portion of the pseudoephedrine can be incorporated as an immediate release component.
EP 1404304 A1 A tablet comprising at least two distinct segments one segment of which comprises as active ingredient predominantly cetirizine and a second segment of which comprises as active ingredient predominantly pseudoephedrine.
WO2010/078541 describes a pharmaceutical composition comprising drug layer comprising drug particles comprising naproxen and cetirizine and another drug layer comprising pseudoephedrine, for treating symptoms of upper respiratory allergies, nasal congestion, and headache.
Summary of the invention
An effervescent pharmaceutical composition, characterized in that it comprises:
a) pseudoephedrine or pharmaceutically acceptable salt thereof,
b) levocetirizine or pharmaceutically acceptable salt thereof,
in combination with at least one pharmaceutically acceptable excipient.
In a most preferred embodiment, present invention relates to an effervescent composition comprising:
a) 5-10 mg of levocetirizine,
b) 30-60 mg of pseudoephedrine,
c) citric acid,
d) sodium bicarbonate, and
e) at least one flavor.
As used herein the term "levocetirizine" means levocetirizine or pharmaceutically acceptable salt thereof. As used herein the term "pseudoephedrine" means pseudoephedrine or pharmaceutically acceptable salt thereof.
Effervescent formulation of the present invention can be in powder, granule or tablet form. Effervescent formulation of the present invention is preferably in tablet form.
In a preferred embodiment, the composition of the present invention is in the form of an effervescent tablet intended to be dissolved or dispersed in water before administration and generally contains acid substances and carbonates or bicarbonates, which react rapidly in the presence of water releasing carbon dioxide. The effervescent tablets comprise effervescent couples selected from, but not limited to, thermolabile gas generating agents such as sodium bicarbonate, sodium glycine carbonate, potassium bicarbonate, ammonium bicarbonate, sodium bisulfite, sodium metabisulfite, and an acid source such as citric acid, maleic acid or tartaric acid.
Different carbonates, acids and buffers are used to attain good effervescence in short time and to obtain a clear solution, and to give maximum therapeutic effect in short time.
In one embodiment, in the compositions of the present invention, acid and base components are in the separate compartments.
Compositions of this invention may be used in the treatment of vasomotor rhinitis. It can be reduced rhinitis and asthma symptoms and improved overall quality of life. It is indicated for the relief of nasal and non-nasal symptoms associated with seasonal or perennial allergic rhinitis in adults and children 12 years of age and older.
This invention can be used for the treatment of allergies, hay fever, pollen, dust, mold and tree allergies. In addition, this invention is used to relieve allergy symptoms such as watery eyes, runny/stuffy nose, itching eyes/nose, and sneezing.
This invention may be used for the treatment of nasal congestion, sinus congestion, Eustachian tube congestion, and vasomotor rhinitis, and as an adjunct to other agents in the optimum treatment of allergic rhinitis, croup, sinusitis, otitis media, and tracheobronchitis.
In this present invention, it shows quick affect and efficiency.
This invention can include production method which is for increasing solubility. This method can be used in wet granulation.
An important subject of the present invention is to provide a formulation which has resistant against physical and enviromental conditions and also have a high bioavailability.
The present invention provides pharmaceutical formulations comprising active ingredients combination characterized by 1) good stability properties, 2} controfiing the release of the active ingredient according to desired therapeutical needs, and finally 3) simple and also competitive manufacturing process.
We have now surprisingly found that levocetirizine may be effectively combined with pseudoephedrine, comparing with single activity of each of these and with an enhancement of the activity of pseudoephedrine and other compounds.
Pharmaceutical composition of the present invention may comprise one or more pharmaceutically acceptable excipient(s). Pharmaceutically acceptable excipients comprise, but are not limited to, fillers, disintegrants, solvents, acid substance, base substance, binders, lubricants, glidants, sweeteners, aromatic agents, flavouring agents, preservatives, coloring agents, and the mixtures thereof.
Binders can be selected from the group, but are not limited to, methylcellulose, sodium carboxymethycellulose, calcium carboxymethycellulose, ethylcellulose, hydroxypropyl methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, silicified microcrystalline cellulose(SMCC), polyvinylpyrrolidone, gelatine, polyvinyl alcohol, acacia, tragacanth, guar, pectin, starch paste, potato starch, corn starch, wheat starch, pre-gelatinized starch, alginic acid, compressible sugar, liquid glucose, dextrates, dextrin, dextrose, ma!todextrin, guar gum, magnesium aluminium silicate, polymethacrylates, sorbitol, natural-synthetic gums and other materials known to one of ordinary skill in the art. A mixture of binders may also be used.
Diluents may be water-soluble or water insoluble. Diluents can be selected from the group, but are not limited to, spray-dried or anhydrous lactose, sucrose, dextrose, starch, pre-geiatinized starch, mannitol, maltitol, sorbitol, xylitol, dextrin, cellulose derivatives including powdered cellulose, microcrystalline cellulose, dibasic calcium phosphate, tribasic calcium phosphate and calcium sulphate, kaolin, precipitated calcium carbonate, maltodextrin and other materials known to one of ordinary skill in the art. A mixture of diluents may also be used.
Lubricants can be selected from the group, but are not limited to, vegetable oils, such as hydrogenated vegetable oil or hydrogenated castor oil; polyethylene glycols, such as polyethylene glycol (PEG)-4000 and PEG-6000; stearic acid; derivatives of stearic acid, such as magnesium stearate, sodium stearate, calcium stearate, zinc stearate, glyceryl monostearate, glyceryl palmitostearate and sodium stearyl fumarate; mineral salts, such as talc; inorganic salts; organic salts, such as sodium benzoate, sodium acetate, sodium chloride and sodium oleate; and polyvinyl alcohols, microcrystalline cellulose, sodium lauryl sulphate, silica, colloidal silica, cornstarch, calcium silicate, magnesium silicate, silicon hydrogel and other materials known to one of ordinary skill in the art.A mixture of lubricants may also be used.
Gtidants can be selected from the group, but are not limited to, colloidal silicon dioxide, colloidal silica, cornstarch, talc, calcium silicate, magnesium silicate, magnesium trisiiicate, amorphous silica, colloidal silicon, silicon hydrogel, powdered cellulose, silicon dioxide, talc, tribasic calcium phosphate and other materials known to one of ordinary skill in the art. A mixture of glidants may also be used.
Flavoring agents, including, but not limited to, black current, sodium chloride, strawberry, peppermint, menthol, artificial vanilla, cinnamon, various fruit flavors, natural aroma oils (such as peppermint oil, oil of wintergreen, clove bud oil, parsley oil, eucalyptus oil, lemon oil, orange oil), menthane, anethole, methyl salicylate, eucalyptol, methyl acetate, sage, 1-eugenol, oxanon, alpha-irisone, marjoram, lemon, orange, blackberry, propenyl guaetol acetyl, vanilla, timole, linalol, cinnamaldehyde glycerol acetal, N-substituted p-menthane-3-carboxamide and other materials known to one of ordinary skill in the art. A mixture of flavoring agents may also be used.
Sweeteners, including, but not limited to, sugars such as sucrose, glucose (corn syrup), invert sugar, fructose, and mixtures thereof; saccharin and its various salts such as sodium or calcium salt; cyclamic acid and its various salts such as sodium salt; the dipeptide sweeteners such as aspartame; dihydrochalcone; glycyrrhizin; Stevia rebaudiana (Stevioside); and sugar alcohols such as sorbitol, sorbitol syrup, D- tryptophan, monoammonium glycyrrhizinate, neohesperidin, dihydrochalcone, thaumatin, neotam, alitam, cyclamates,mannitol, xylitol, and the like. A combination of sweeteners and flavoring agents can also be used.
Buffering agents can be selected from the group, but not limited to, potassium bicarbonate, citric acid, glycine, arginine, sodium acetate and sodium citrateand other materials known to one of ordinary skill in the art, and the mixtures thereof.
Acid substance can be selected from the group, but not limited to, ascorbic acid, citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, lactic acid, oxalic acid, formic acid, benzene sulfonic add, benzoic acid, maleic acid, glutamic acid, succinic acid, aspartic acid, diatrizoic acid, acetic acid and acid anhydrides and acid salts thereof, and mixtures thereof. The acidifying agent may also be an inorganic acid, such as hydrochloric acid, sulfuric acid, phosphoric acid, and nitric acid.
Base substance can be selected from the group, but not limited to, aluminum salts such as magnesium aluminum silicate; magnesium salts such as magnesium carbonate, magnesium trisiiicate, magnesium stearate; calcium salts such as calcium carbonate; bicarbonates such as calcium bicarbonate and sodium bicarbonate; phosphates such as monobasic calcium phosphate, dibasic calcium phosphate, dibasic sodium phosphate, tribasic sodium phosphate (TSP), dibasic potassium phosphate, tribasic potassium phosphate; metal hydroxides such as
aluminum hydroxide, sodium hydroxide and magnesium hydroxide; metal oxides such as magnesium oxide; N-methyl glucami'ne; arginine and salts thereof; amines such as monoethanolamine, diethanolamine, triethanolamine, and tris(hydroxymethyl)aminomethane (TRIS) and other materials known to one of ordinary skill in the art, and the mixtures thereof. The pharmaceutical formulation are produced by one of the dry granulation, dry blending, direct compression, wet granulation methods.
The method proposed for production of the formulations of the present invention is preferably wet granulation method and it basically comprises the following steps;
a. Preparation of the granulation solution,
b. Granulation,
c. Drying and sieving,
d. Tablet compression.
The granulation solution to be used in the production of the formulations of the present invention comprise a pharmaceutically acceptable solvent in an effective amount and at least one binder.
Example 1
Claims
1. An effervescent pharmaceutical composition, characterized in that it comprises;
a) levocetirizine or pharmaceutically acceptable salt thereof,
b) pseudoephedrine or pharmaceutically acceptable salt thereof,
in combination with at least one pharmaceutically acceptable excipient.
2. An effervescent composition according to claim 1 , wherein it comprises levocetirizine dihydrochloride in an effective amount.
3. An effervescent composition according to claim 1 , wherein it comprises pseudoephedrine hydrochloride in an effective amount.
4.An effervescent composition according to any one of the preceeding claims, it comprises at least one acid component selected from the group consisting of citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid, acid anhydrides and acid salts thereof, and mixtures thereof and at least one base component selected from the group consisting of carbonate salts, bicarbonate salts, phosphate salts, and mixtures thereof.
5. An effervescent composition according to claim 4, wherein acid component is citric acid and base component is sodium bicarbonate.
6. An effervescent composition according to claim 1 , wherein it comprises at least one sweetener agent.
7. An effervescent composition according to claim 6, wherein said sweetener is selected from a group comprising synthetic and natural sugars; sucrose, sucralose, saccharine, aspartame, acesulfame, thaumatin, dextrose, mannitol, maltitol, lactose, xylitol, isomalt, isomaltol, lactitol, eryhtrol, maltodextrin, alpha, beta and gamma cyclodextrins, dihydrochalcone, alitam, sorbitol, sodium cyclamate, miraculin, moneltin, steviocide and/or pharmaceutically acceptable salts thereof.
8. An effervescent composition according to claim 7, wherein said sweetener is sucralose and/or aspartame and/or acesulfame potassium.
9. An effervescent composition according to claim 1 , wherein it comprises at least one flavoring agent.
10. An effervescent composition according to claim 9,wherein flavoring agent is a combination of lemon and blackberry.
11. An effervescent composition according to any one of the preceeding claims, comprising: a) 5-10 mg of levocetirizine or pharmaceutically acceptable salt thereof,
b) 30-60 mg of pseudoephedrine or pharmaceutically acceptable salt thereof,
c) citric acid,
d) sodium bicarbonate, and
e) at least one flavor.
12. An effervescent composition according to any one of the preceeding claims, comprising: a) 5 mg of levocetirizine or pharmaceutically acceptable salt thereof,
b) 60 mg of pseudoephedrine or pharmaceutically acceptable salt thereof,
c) citric acid,
d) sodium bicarbonate, and
e) at least one flavor.
13 An effervescent composition according to to any one of the preceeding claims, wherein it is in the form of powder, granule or tablet.
14. An effervescent composition according to claim 13, wherein it is a tablet.
15. An effervescent composition according to claim 14, wherein acid and base components are in the separate compartments.
16. An effervescent composition according to claim 15, wherein levocetirizin or pharmaceutical acceptable salt and pseudoefedrin or pharmaceutical acceptable salt and acid component are in the same compartment.
17. An effervescent composition according to any preceeding claims, for the manufacture of a medicament for preventing or treating disorders or conditions associated with rhinitis and asthma symptoms, allergies and symptoms, hay fever.sinus congestion, Eustachian tube congestion,croup, sinusitis, otitis media, tracheobronchitis, relief of nasal congestion, seasonal rhinitis, sneezing, rhinorrhea, nasal and ocular pruritus, redness of theeyes, tearing, sneezing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/TR2015/000089 WO2016140630A1 (en) | 2015-03-05 | 2015-03-05 | An effervescent composition comprising levocetirizine and pseudoephedrine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/TR2015/000089 WO2016140630A1 (en) | 2015-03-05 | 2015-03-05 | An effervescent composition comprising levocetirizine and pseudoephedrine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2016140630A1 true WO2016140630A1 (en) | 2016-09-09 |
Family
ID=52815255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2015/000089 WO2016140630A1 (en) | 2015-03-05 | 2015-03-05 | An effervescent composition comprising levocetirizine and pseudoephedrine |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2016140630A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111214449A (en) * | 2020-03-02 | 2020-06-02 | 广东彼迪药业有限公司 | Cetirizine hydrochloride tablet and preparation method thereof |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995003785A1 (en) * | 1993-08-03 | 1995-02-09 | Warner-Lambert Company | Pleasant tasting effervescent cold/allergy medications |
| EP0811374A1 (en) | 1996-05-29 | 1997-12-10 | Pfizer Inc. | Combination dosage form comprising cetirizine and pseudoephedrine |
| EP1404304A1 (en) | 2001-06-28 | 2004-04-07 | UCB Farchim S.A. | Tablet comprising cetirizine and pseudoephedrine |
| US20070048375A1 (en) * | 2003-12-19 | 2007-03-01 | Wolfgang Wiehl | Effervescent preparation of a basic medicinally active substance |
| WO2010078541A1 (en) | 2009-01-05 | 2010-07-08 | Mcneil-Ppc, Inc. | Tablet containing coated particles of cetirizine, pseudoephedrine, and/or naproxen |
| WO2011146032A2 (en) | 2010-05-18 | 2011-11-24 | Mahmut Bilgic | Effervescent formulations |
| WO2012064300A2 (en) * | 2010-11-11 | 2012-05-18 | Mahmut Bilgic | Desloratadine granules |
| US20120301548A1 (en) * | 2010-02-01 | 2012-11-29 | Hanmi Science Co., Ltd | Oral complex composition comprising pseudoephedrine and levocetirizine |
| WO2013058721A1 (en) * | 2011-10-13 | 2013-04-25 | Mahmut Bilgic | Pharmaceutical granules and production method |
-
2015
- 2015-03-05 WO PCT/TR2015/000089 patent/WO2016140630A1/en active Application Filing
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995003785A1 (en) * | 1993-08-03 | 1995-02-09 | Warner-Lambert Company | Pleasant tasting effervescent cold/allergy medications |
| EP0811374A1 (en) | 1996-05-29 | 1997-12-10 | Pfizer Inc. | Combination dosage form comprising cetirizine and pseudoephedrine |
| US6171618B1 (en) | 1996-05-29 | 2001-01-09 | Pfizer Inc. | Combination dosage form comprising cetirizine and pseudoephedrine |
| US20020012700A1 (en) * | 1996-05-29 | 2002-01-31 | Johnson Barbara A. | Combination dosage form comprising cetirizine and pseudoephedrine |
| EP1404304A1 (en) | 2001-06-28 | 2004-04-07 | UCB Farchim S.A. | Tablet comprising cetirizine and pseudoephedrine |
| US20070048375A1 (en) * | 2003-12-19 | 2007-03-01 | Wolfgang Wiehl | Effervescent preparation of a basic medicinally active substance |
| WO2010078541A1 (en) | 2009-01-05 | 2010-07-08 | Mcneil-Ppc, Inc. | Tablet containing coated particles of cetirizine, pseudoephedrine, and/or naproxen |
| US20120301548A1 (en) * | 2010-02-01 | 2012-11-29 | Hanmi Science Co., Ltd | Oral complex composition comprising pseudoephedrine and levocetirizine |
| WO2011146032A2 (en) | 2010-05-18 | 2011-11-24 | Mahmut Bilgic | Effervescent formulations |
| WO2012064300A2 (en) * | 2010-11-11 | 2012-05-18 | Mahmut Bilgic | Desloratadine granules |
| WO2013058721A1 (en) * | 2011-10-13 | 2013-04-25 | Mahmut Bilgic | Pharmaceutical granules and production method |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111214449A (en) * | 2020-03-02 | 2020-06-02 | 广东彼迪药业有限公司 | Cetirizine hydrochloride tablet and preparation method thereof |
| CN111214449B (en) * | 2020-03-02 | 2021-09-07 | 广东彼迪药业有限公司 | Cetirizine hydrochloride tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100653568B1 (en) | Solid, quick dissolving cetirizine formulations | |
| EP3013323B1 (en) | Complex granule formulation having improved stability comprising levocetirizine and montelukast | |
| EP3003384B1 (en) | Oral solution comprising atomoxetine hydrochloride | |
| KR20100086140A (en) | A composition of fast dissolving tablets containing montelukast and it's manufacturing thereof | |
| US10064820B2 (en) | Antihistamine compositions, combinations, and use thereof | |
| WO2011136751A2 (en) | Water soluble pharmaceutical composition | |
| WO2016140630A1 (en) | An effervescent composition comprising levocetirizine and pseudoephedrine | |
| JP2018188377A (en) | Pharmaceutical composition | |
| EP2571485B1 (en) | Effervescent antihistamine formulations | |
| EP2481395A1 (en) | Sachet, effervescent tablet and dry syrup of otilonium | |
| EP2959889A1 (en) | Orally disintegrating formulations of loxoprofen | |
| WO2015117987A1 (en) | Effervescent formulations comprising ibuprofen and n-acetylcystein | |
| US9265757B2 (en) | Methods of administering antihistamines | |
| AU2019306315B2 (en) | Pharmaceutical composition in the form of a chewable tablet of diosmin or of a flavonoid moiety | |
| EP2566450A2 (en) | Pharmaceutical compositions comprising cefetamet | |
| JP2006342188A (en) | Intraoral dissolution type or chewable solid internal medicine composition for treating rhinitis | |
| EP3095466B1 (en) | Pharmaceutical formulations with improved solubility and stability | |
| WO2021194446A1 (en) | A sachet formulation comprising metformin and dapagliflozin | |
| KR20230022941A (en) | Bioavailable sugar-based diclofenac formulation | |
| WO2023126637A1 (en) | Compositions containing fexofenadine | |
| US20050043296A1 (en) | Compositions and methods for treating sexual dysfunction | |
| TR201508678A2 (en) | Pharmaceutical ingredients | |
| TR201508674A2 (en) | Pharmaceutical compositions | |
| KR20160012921A (en) | Oral fast dissolving formulation containing blonanserin | |
| KR20130076529A (en) | Oral atomoxetine chewable tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15714982 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 15714982 Country of ref document: EP Kind code of ref document: A1 |